Alternative Viewpoint Listing
January 2009
Tebbe SR. Conflicting Data: Association of Proton Pump Inhibitors and Risk of Osteoporotic Fractures
commenting on Kaye JA and Jick H. Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors. Pharmacotherapy 2008;28(8):951-959.
October 2008
Wargo KA. Clincial Judgment: To Renal Dose Adjust Antimicrobials or Not
commenting on Golik MV, Lawrence KR. Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: Cockcroft-Gault and Modification of Diet in Renal Disease. Pharmacotherapy 2008;28(9):1125-1132.
Hunt J. The Future of Advanced Pharmacy Practice: Wildcats versus Zeroes
September 2008
Ambrosini MT. Autoimmunity and Schizophrenia
commenting on Goldsmith CW, Rogers DP. The Case for Autoimmunity in the Etiology of Schizophrenia. Pharmacotherapy 2008;28(6):730-741.
Csajka C, Cavassini M, Rotger M, et al. Efavirenz Dose Adjustment in HIV Patients with Impaired CYP2B6 Function.
Commenting on Torno MS, Witt MD, Saitoh A., et al. Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: Case report and review of the literature. Pharmacotherapy 2008;28(6):782-787.
July 2008
Clay PG. Research Publications by Pharmacists: Kudos and Questions
commenting on Touchette DR, Bearden DT, Ottum SA. Research publications by pharmacist authors in major medical journals: changes over a 10-year interval. Pharmacotherapy 2008;28(5):584-90.
April 2008
Ensom RJ, Ensom MHH. Will Genetic Testing for Warfarin Dosing Ever Be Ready for Prime Time?
commenting on Bussey HI, Wittkowsky Ak, Hylek EM, Walker MB. Genetic testing for warfarin dosing? Not yet ready for prime time. Pharmacotherapy 2008:28(2):141-3.
March 2008
Leung S, Poulakos MN, Ramirez-Ruiz L. Comparing Unbound Plasma Posaconazole Levels to Fungal Minimal Inhibitory Concentrations (MICs) in Allogenic Hematopoietic Stem Cell Transplant (HSCT) Recipients with Graft-Versus-Host Disease (GVHD)
commenting on Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral Posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007;27(12):1627-36.
Marrs JC, Saseen JJ. Debating the Clinical Benefits of Ranolazine and its Role in Therapy
commenting on Dobesh PP, Trujillo TC. Ranolazine: a new option in the management of chronic stable angina. Pharmacotherapy 2007;27(12):1659-76.
February 2008
Mascitelli L, Pezzetta F, Goldstein MR. Statin Therapy and Intracerebral Hemorrhage
commenting on Weant KA, Cook AM. Potential roles for statins in critically ill patients. Pharmacotherapy 2007;27(9):1279-96.
January 2008
Gerhard T, Zineh I, Winterstein AG, Hartzema AG. Uncertain Economic Impact of Nesiritide in Advanced Decompensated Heart Failure
commenting on Munger MA, Ng TM, Van Tassell BW. Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment. Pharmacotherapy. 2007;27(5):619-625.
Leung S, Poulakos MN, Kernan W. Is the Drug Interaction Actual between Posaconazole and Cyclosporine?
commenting on Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007;27(6):825-34.
Doloresco F, Vermeulen LC. Insufficient Evidence of Equivalence—Alternate Dosing of Meropenem
commenting on Patel GW, Duquaine SM, McKinnon PS. Clinical Outcomes and Cost Minimization with an Alternative Dosing Regimen for Meropenem in a Community Hospital. Pharmacotherapy 2007;27(12):1637-43.
September 2007
Slavik RS, Gorman SK. Error Rates Among Clinical Pharmacists in Calculating the APACHE II Score
commenting on Greenwood B, Szumita PM, Levy H, Lilly CM. Error rates among clinical pharmacists in calculating the APACHE II score. Pharmacotherapy 2007;27(2):285-289.
Bantar C. Tigecycline: Searching the Rationale to the Enforced Off-Level Usage
commenting on Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007;27:1198–1201.
August 2007
Schwenk MH. Safe Administration of Iron Sucrose in a Patient with a Previous Hypersensitivity Reaction to Ferric Gluconate—Comment
commenting on Sane R, Baribeault D, Rosenberg CL. Safe administration of iron sucrose to a patient with a history of previous hypersensitivity reactions to sodium ferric gluconate. Pharmacotherapy 2007;27(4):613–615.
July 2007
Faus MJ, Sabater-Hernándex D, Amariles P. Types of Pharmacist Interventions Intended to Prevent and Solve Negative Outcomes Associated with Medication.
commenting on Hoth AB, Carter BL, Ness J, Bhattacharyya, Shorr RI, Rosenthal GE, Kaboli PJ. Development and Reliability Testing of the Clinical Pharmacist Recommendation Taxonomy. Pharmacotherapy 2007;27(5):639-46.
May 2007
Wiens B, Levine M, Jafari S, Etminan M. Immortal Time Bias in Effects of Lipid Lowering Agents on Pneumonia.
commenting on Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. Statins and the Risk of Pneumonia: A Population-Based, Nested Case-Control Study. Pharmacotherapy 2007;27(3):325-332.
Riche DM. Impracticality of Cinnamon Supplements in Diabetes.
commenting on Pham AQ, Kourlas H, Pham DQ. Cinnamon supplementation in patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27(4):595-9.
April 2007
Hubbe M. Pharmacoeconomic Evaluation of Antimuscarinic Agents: Bias toward Solifenacin?
commenting on Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy. 2006;26(12):1694-1702.
Gabardi S. Factors Influencing the Magnitude and Clinical Significance of Drug Interactions between Azole Antifungals and Select Immunosuppressants
commenting on Saad AH, Depestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26(12):1730-44.
March 2007
Lucas Jr BD, Lucas KH, Reyes BJ. More on NSAIDs and Cardiovascular Risk
commenting on response by Stacy ZA, Dobesh PP, Trujillo TC to Cardiovascular risks of cyclooxygenase inhibition. Pharmacotherapy 2006;26:e125-128.
January 2007
Abanades S, Pardo-Lozano R, Farré M. New Insights on Cefepime Associated Neurotoxicity
commenting on Lam S, Gomolin IH. Cefepime neurotoxicity: Case report, pharmacokinetic considerations, and literature review. Pharmacotherapy. 2006;26(8):1169-74.
November 2006
Krantz MJ, Schmittner J. Pleiotropic Effects of Statin Drugs: Clinical Paradigm or Research Fiction?
commenting on Ito MK, Talbert RL, Tsimikas S. Statin-Associated Pleiotropy: Possible Beneficial Effects Beyond Cholesterol Reduction (Pharmacotherapy 2006;26(7 pt 2):85S-97S.
Lucas Jr BD, Lucas KH, Reyes BJ. Cardiovascular Risks of Cyclooxygenase Inhibition
commenting on Stacy ZA, Dobesh PP, Trujillo TC. Cardiovascular risks of cyclooxygenase inhibition. Pharmacotherapy 2006;26(7):919-38.